WuXi AppTec Achieves Remarkable Financial Milestones in Q1 2026

Overview

WuXi AppTec, a premier global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announced its financial results for the first quarter of 2026, showcasing significant growth in both revenue and profit metrics. The company's total revenue reached RMB 12.44 billion, marking an impressive 28.8% year-over-year increase. Furthermore, revenue from continuing operations rose by 39.4%, emphasizing the company's robust operational performance.

Strong Financial Performance

The report highlighted a substantial surge in adjusted non-IFRS net profit, which rose by 71.7% year-over-year to RMB 4.60 billion. Alongside this profit boost, the company's adjusted non-IFRS net profit margin experienced an increase of 9.2 percentage points, achieving 37.0%. The outcome reflects WuXi's effective cost management and operational efficiencies, which have greatly contributed to its profitability. The adjusted operating cash flow also saw a notable rise of 21.7%, driven by ongoing business growth and efficient financial management practices.

Backlog and Growth Initiatives

WuXi AppTec reported a backlog for continuing operations reaching RMB 59.77 billion, an increase of 23.6% year-over-year. This growth is indicative of the company's strong CDMO business model, which successfully meets the escalating needs of its clients. Dr. Ge Li, the company's Chairman and CEO, expressed confidence in WuXi AppTec's trajectory, citing the strength of its current performance and the proactive capacity planning that aims to enhance operational and management resilience. WuXi’s strategies, encapsulated in the